Go Pro
NASDAQ:DRTS

Alpha Tau Medical Q2 2026 Earnings Report

Alpha Tau Medical logo
$14.40 -0.04 (-0.24%)
As of 02:57 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Alpha Tau Medical EPS Results

Actual EPS
-$0.50
Consensus EPS
-$0.14
Beat/Miss
Missed by -$0.36
One Year Ago EPS
N/A

Alpha Tau Medical Revenue Results

Actual Revenue
N/A
Expected Revenue
$0.14 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Alpha Tau Medical Announcement Details

Quarter
Q2 2026
Time
After Market Closes
Conference Call Date
Monday, August 10, 2026
Conference Call Time
4:00PM ET

Upcoming Earnings

Alpha Tau Medical's Q3 2026 earnings is estimated for Thursday, November 19, 2026, based on past reporting schedules, with a conference call scheduled on Monday, November 16, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Earnings Documents

Alpha Tau Medical Earnings Headlines

Musk says UBI is coming. I say it's already here.
Elon Musk says AI could make money irrelevant by 2036. One income program already exists today, funded not by robots but by America's oil and gas infrastructure. It's called the Patriot Income Plan, or P.I.P., and it pays 10% a year across 42 separate distribution dates. This year it's on track to pay out a record 53 billion dollars. Think of it as a personal stake in the world's largest energy producer, structured to deliver income on a regular schedule.tc pixel
Alpha Tau to Participate in September Investor Conferences
See More Alpha Tau Medical Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Alpha Tau Medical? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Alpha Tau Medical and other key companies, straight to your email.

About Alpha Tau Medical

Alpha Tau Medical (NASDAQ:DRTS) is an Israel-based biotechnology and medical technology company developing targeted alpha radiation therapies for the treatment of solid tumors. Its lead technology, Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy), is designed to deliver localized alpha radiation directly within a tumor while limiting exposure to surrounding healthy tissue.

Alpha DaRT uses radium-224 sources placed into or near a tumor. As the radium decays, its short-range alpha-emitting products are intended to diffuse through the tumor and destroy cancer cells. The company has evaluated the technology in clinical studies across several cancer indications, including cutaneous squamous cell carcinoma and other solid tumors.

Alpha Tau was founded in Israel and has conducted research and clinical development activities in Israel, the United States and other international locations. The company is led by Chief Executive Officer Uzi Sofer and continues to focus on advancing Alpha DaRT through clinical development and potential regulatory approval for cancer treatment.

View Alpha Tau Medical Profile